Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Phone app boosts cancer screening rates in large trial

NCT ID NCT06821009

Prevention Sponsor: Digital Health Navigation Solutions, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a cloud-based digital program called mPATH-CRC that helps people aged 45-74 complete colorectal cancer screening. Participants use a link sent by text to access the program on their own phone, where they can learn about screening and request a test directly. The goal is to see if this approach increases screening rates in two different healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 45-74 years 2. Be identified in the electronic health record as due for routine CRC screening, defined as 1. No colonoscopy in prior 10 years 2. No flexible sigmoidoscopy in prior 5 years 3. No CT colography in prior 5 years 4. No FIT-DNA test (Cologuard) within prior 3 years 5. No Fecal Occult Blood Test within prior 1 year 3. Have a cell phone number listed in the EHR 4. Have a preferred language of English or Spanish in the EHR 5. Upcoming appointment within 9 to 16 days 6. Georgia Market Only: Insurance type is listed as Medicare Advantage. Exclusion Criteria 1. Prior diagnosis of colorectal cancer 2. Prior history of total colectomy 3. Currently enrolled in palliative care or Hospice 4. Age over 65 AND currently enrolled in an Institutional SNP (I-SNP) or living in Long Term Care 5. Age over 65 with frailty and advanced illness (as defined by the health system's My Panel metric which mirrors the HEDIS COL-E quality metric for CRC screening)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer screening are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer screening

Contacts and locations

Locations

  • Atrium Health Floyd

    Rome, Georgia, 30161, United States

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.